ACG Wealth’s Oramed Pharmaceuticals ORMP Stock Holding History

ACG Wealth’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-400	Closed	-$2K	–	777
2022 Q2	$2K	Buy	+400	New	+$2.14K	﹤0.01%	826

Other funds holding ORMP

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACG Wealth's ORMP Position: Q3 2022 in Review

ACG Wealth sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 400 shares — an estimated $2K sold.

ACG Wealth first reported a position in ORMP in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

ACG Wealth reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
ACG Wealth sold 400 Oramed Pharmaceuticals shares in Q3 2022, an estimated $2K.
ACG Wealth first reported a position in Oramed Pharmaceuticals in Q2 2022 and held it in 1 quarter.
ACG Wealth's Oramed Pharmaceuticals position peaked at $2K in Q2 2022.
71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.